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Imatinib Reverses Doxorubicin Resistance by Affecting
Activation of STAT3-Dependent NF-kB and HSP27/p38/
AKT Pathways and by Inhibiting ABCB1
Jonathan T. Sims, Sourik S. Ganguly, Holly Bennett, J. Woodrow Friend, Jessica Tepe, Rina Plattner*
Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, Kentucky, United States of America
Abstract
Despite advances in cancer detection and prevention, a diagnosis of metastatic disease remains a death sentence due to the
fact that many cancers are either resistant to chemotherapy (conventional or targeted) or develop resistance during
treatment, and residual chemoresistant cells are highly metastatic. Metastatic cancer cells resist the effects of
chemotherapeutic agents by upregulating drug transporters, which efflux the drugs, and by activating proliferation and
survival signaling pathways. Previously, we found that c-Abl and Arg non-receptor tyrosine kinases are activated in breast
cancer, melanoma, and glioblastoma cells, and promote cancer progression. In this report, we demonstrate that the c-Abl/
Arg inhibitor, imatinib (imatinib mesylate, STI571, Gleevec), reverses intrinsic and acquired resistance to the anthracycline,
doxorubicin, by inducing G2/M arrest and promoting apoptosis in cancer cells expressing highly active c-Abl and Arg.
Significantly, imatinib prevents intrinsic resistance by promoting doxorubicin-mediated NF-kB/p65 nuclear localization and
repression of NF-kB targets in a STAT3-dependent manner, and by preventing activation of a novel STAT3/HSP27/p38/Akt
survival pathway. In contrast, imatinib prevents acquired resistance by inhibiting upregulation of the ABC drug transporter,
ABCB1, directly inhibiting ABCB1 function, and abrogating survival signaling. Thus, imatinib inhibits multiple novel
chemoresistance pathways, which indicates that it may be effective in reversing intrinsic and acquired resistance in cancers
containing highly active c-Abl and Arg, a critical step in effectively treating metastatic disease. Furthermore, since imatinib
converts a master survival regulator, NF-kB, from a pro-survival into a pro-apoptotic factor, our data suggest that NF-kB
inhibitors may be ineffective in sensitizing tumors containing activated c-Abl/Arg to anthracyclines, and instead might
antagonize anthracycline-induced apoptosis.
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Introduction
The goal of chemotherapy is to kill disseminated cancer cells
and prevent metastatic progression; however, many cancers are
intrinsically resistant to conventional chemotherapeutic agents,
and others that initially respond, develop resistance (acquired)
during treatment [1]. The anthracycline, doxorubicin, a topo-
isomerase II inhibitor, is used to treat many cancers, such as triple-
negative (ER2, PR2, Her-22) breast cancer; however, resistance
arises for many cases [2,3]. For other cancers, such as melanoma,
doxorubicin is not routinely utilized due to intrinsic resistance [4].
Thus, although doxorubicin is a highly effective agent, its use is
limited due to resistance as well as due to its narrow therapeutic
window (e.g. cardiac toxicity) [5]. Drug resistance has been linked
to upregulation of efflux molecules (ABC transporters), which play
a role in both intrinsic and acquired chemoresistance [6].
Numerous transporters have been implicated in chemoresistance;
however, ABCB1 (MDR-1, P-gp), ABCC1 (MRP1), and ABCG2
(BCRP) have been most extensively studied [7]. Activation of a
variety of pathways including FOXO3a, PI3K/Akt, NF-kB, and
extracellular signal-regulated kinase (ERK), as well as HSP27
depletion have been implicated in ABC transporter upregulation
[8–10].
Activation of proliferation and survival signaling pathways also
contribute to chemoresistance. Signal Transducer and Activator of
Transcription (STAT3) and NF-kB transcription factors, promote
oncogenesis, increasing proliferation, survival, invasion, and
metastasis by promoting transcription of pro-proliferative, pro-
invasive, and anti-apoptotic genes [11–14]. The NF-kB family,
which consists of p65 (RelA), RelB, p50/105 (NF-kB1), c-Rel, and
p52/p100 (NF-kB2), are constitutively activated in many cancers
[14]. NF-kB is activated via the canonical pathway by Inhibitor of
kB kinase (IKKb)–dependent phosphorylation and degradation of
IkB (which normally binds and inhibits p50/p65 dimers from
entering the nucleus) [14]. NF-kB dimers translocate into the
nucleus where they bind NF-kB response elements and promote
transcription [14]. NF-kB post-translational modifications (e.g.
phosphorylation and acetylation) regulate its nuclear localization,
DNA binding, oligomerization, interaction with coactivators/
corepressors, and transactivation [14]. NF-kB promotes survival
by inducing expression of anti-apoptotic proteins; however,
accumulating evidence suggests that NF-kB also can promote
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apoptosis and serves as a tumor suppressor in some tumor types
[14,15]. Similarly, in some cell types and in response to some
agents, NF-kB promotes chemoresistance whereas in other cell
types DNA damaging agents activate NF-kB and convert it into a
repressor that inhibits transcription of anti-apoptotic genes and
promotes apoptosis [16–22]. Activation of the phosphoinositide 3-
kinase (PI3K/)Akt pathway also is critical for cancer development,
progression and chemoresistance [23,24]. PI3K activates PDK1,
which membrane localizes and phosphorylates Akt (T308) [24].
Akt is further activated by phosphorylation on a second residue
(S473) via mTORC2 (in response to growth factors), p38/MK2
(MAPKAPK-2; in neutrophils and neuronal cells) or DNA-PK (in
response to insulin, pervanadate in glioblastoma cells) [25–28].
Active p38/MK2 promotes phosphorylation of the scaffold
protein, HSP27, which recruits Akt, and Akt is phosphorylated
on S473. Active Akt, in turn, phosphorylates HSP27, mediating its
dissociation from the complex, and Akt also phosphorylates
numerous other substrates involved in cell proliferation, survival,
translation, and metabolism [24,25,28,29].
The Abl family of non-receptor tyrosine kinases (c-Abl/Arg) are
most known for their involvement in the development of human
leukemia; however, recently, we provided evidence that they also
promote solid tumor progression [30–33]. Here, we demonstrate
that inhibition of c-Abl/Arg in cells with high c-Abl/Arg activity
abrogates doxorubicin resistance by inducing G2/M cell cycle
arrest and apoptosis, blocking activation of a novel Akt survival
pathway, promoting repression of NF-kB targets, and preventing
expression and function of ABCB1. Thus, in combination with c-
Abl/Arg inhibitors, doxorubicin may be effective in cancers not
previously treated with this agent (e.g. melanoma), and c-Abl/Arg
inhibitors may decrease doxorubicin toxicity in cancers where the
drug currently is used (e.g. breast cancer) by decreasing the
doxorubicin dose required for effective treatment.
Materials and Methods
Cell Lines and Reagents
MDA-MB-435s cells are a spindle-shaped, highly metastatic
variant of MDA-MB-435 cells obtained from ATCC (American
Type Tissue Collection, Manassas, VA) [33]. DNA STR analysis
confirmed that these cells are genetically identical to melanoma
M14, and therefore, are referred to as 435s/M14 [33,34]. Here,
we created a drug-resistant variant of 435s/M14 (435s/M14-DR)
via step-wise treatment with increasing concentrations of doxoru-
bicin (using a maximum dose of 100 nM) [35]. 435s/M14 and
435s/M14-DR cells were cultured in DMEM/10% FBS (fetal
bovine serum)+insulin (10 mg/ml). WM3248 melanoma cells
(derived from a vertical growth phase (VGP) primary melanoma
by Dr. Meenhard Herlyn, Wistar Institute, Philadephia, PA) [36]
were cultured in MCDB153+L-15 (80:20 mixture, respectively)/
2% FBS, insulin (5 mg/ml), calcium chloride (1.68 mM). BT-549
breast cancer cells (obtained from Rolf Craven, University of
Kentucky, Lexington KY who obtained the cells from ATCC)
were cultured in DMEM/10% FBS. Genetic analysis showed
100% identity with ATCC BT-549 cells (Figure S1) [37]. MDA-
MB-468 breast cancer cells (obtained from Eric Stanbridge,
University of California, Irvine who obtained the cells from
ATCC) were cultured in MEM/10% FBS, supplemented with
sodium pyruvate (10 mg/ml). We expressed constitutively active
STAT3 (STAT3C) stably in 435s/M14 cells (obtained from
ATCC) [33]. MCF-7 cells (obtained from ATCC) were stably
transfected with ABCC1 cDNA by Christian Paumi [38]. Cells
expressing GFP-tagged PI3K (E545K) (Addgene; Cambridge,
MA; donated by Jean Zhao) were obtained by transfection
(Lipofectamine 2000; Invitrogen, Carlsbad, CA) followed by G418
(900 mg/ml)/puromycin (1 mg/ml) selection, and flow sorting
GFP-positive cells (University of Kentucky Flow Cytometry
Facility). The 3X-NF-kB reporter construct was provided by Dr.
Denis Guttridge (Ohio State University; Columbus, OH) [39].
Migr1-c-Abl and pK1-Arg [40] were mutated to create imatinib-
resistant c-Abl/Arg expression plasmids (mutation of threonine
315 to isoleucine; AblT/ArgT) [41] (GenScript; Piscataway, NJ).
pK1-ArgT315I was transfected into cells, and expressing cells were
obtained following puromycin selection. ArgT315I-expressing cells
were transiently transfected with Migr1-AblT315I to create c-
AblT315I/ArgT315I-expressing cells.
Imatinib (imatinib mesylate, Gleevec, STI571) and nilotinib
were obtained from Novartis (Basal, Switzerland). Imatinib was
dissolved in water (10 mM) and stored at 280uC, while nilotinib
(10 mM) was dissolved in DMSO, and stored at 4uC. Doxorubi-
cin, paclitaxel, camptothecin, 5-fluorouracil (5-FU), cisplatin,
LY294002, and verapamil were purchased from Sigma (St. Louis,
MO), and rhodamine 123 was purchased from Invitrogen
(Carlsbad, CA). Silencer and Silencer select siRNAs were obtained
from Applied Biosystems/Ambion (Carlsbad, CA): c-Abl (1336-
20 nM), Arg (1478-20 nM), ABCB1 (s10418-5 nM), p65 (s11915-
10 nM), and STAT3 (s743-1 nM). The following antibodies were
purchased commercially: PARP (poly(ADP-ribose) polymerase; sc-
8007), a-tubulin, p65, and Arg (Santa Cruz Biotechnologies; Santa
Cruz, CA); GAPDH and c-Abl (8E9) (BD Biosciences; Chicago,
IL); Lamin A/C, ABCB1, ABCG2, and ABCC1 (Milllipore;
Temecula, CA); b-actin and FLAG (Sigma; St. Louis, MO);
HSP27, XIAP, and cIAP1 (R&D Systems; Minneapolis, MN); and
STAT3, phospho-STAT3 (Y705), phospho-Crk/CrkL (Y221/
Y207), phospho-p38 (T180/T182), p38, Akt, phospho-p65 (S536),
caspase-3, and phospho-Akt (S473) (Cell Signaling Technology;
Danvers, MA).
Cell Lysis/Western Blotting
Treated cells were lysed in RIPA buffer containing fresh
phosphatase/protease inhibitors (50 mM Tris pH 7.5, 150 mM
NaCl, 1% triton-X 100, 0.1% SDS, 1% sodium deoxycholate,
1 mM pefabloc, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM
sodium orthovanadate, 25 mM sodium fluoride), protein quanti-
tated by Lowry DC (Bio-Rad; Hercules, CA), equal protein was
loaded on SDS-PAGE gels, and gels transferred to nitrocellulose.
Western blots were performed as described in the antibody
manufacturers’ protocols. For ABC transporter blots, SDS-PAGE
sample buffer was added to lysates, lysates were frozen at 280uC,
and thawed lysates were loaded on SDS-PAGE gels without
boiling.
CellTiter-Glo Viability Assay (Promega; Madison, WI) [42]
Cells were plated in 96-well plates in triplicate in 100 ml of
medium, refreshed with media containing drugs the following day
when cells were 30–40% confluent, and harvested 72 h later.
CellTiter-Glo reagent (100 ml) was added to each well, the plates
were rocked for 29, incubated at room temperature for 109, 100 ml
was removed from each well, transferred to an opaque 96-well
plate, and luminescence (total light emitted, 100/well) measured
with a Synergy 2 microplate reader (Biotek; Winooski, VT).
Proliferation Assays
Tritiated thymidine assays [42]. Cells were plated in 24-well
plates in triplicate, drug-treated the following day (30–40%
confluent), and harvested after 72 h. Cells were pulsed with
tritiated thymidine (2.5 mCi; 2 h), washed with PBS, incubated in
10% trichloroacetic acid, radioactivity was solubilized in 0.2N
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NaOH, and analyzed on a scintillation counter. Cell cycle
analyses. Cells were plated in 100 mm dishes, refreshed with
media containing drugs the following day when cells were 30–40%
confluent, and harvested after 72 h. Cells were labeled with
bromodeoxyuridine (BrdU, 10 mM) for 1 h at 37uC, trypsinized,
washed and permeabilized with ethanol (70%), stained with
fluorescein isothiocyanate (FITC)-conjugated anti-BrdU antibody
and propidium iodide (PI; 5 mg/ml), and analyzed by fluores-
cence-activated cell sorting (FACS) using Cell Quest software (BD
Biosciences) and Modfit analysis (Verity Software House, Top-
sham, ME).
Apoptosis Assays
PARP and caspase-3 cleavage [42]. Cells were plated in 60 mm
dishes, and treated with drugs the following day (30–40%
confluent). After 40 h, attached and detached cells were lysed in
RIPA buffer (see above), and blots were incubated with PARP,
caspase-3 and GAPDH antibodies. Fluorescent Caspase-3/7 assay
(Sigma; St. Louis, MO) [43]. Cells were plated in 6-well dishes in
triplicate, drug-treated the following day when cells were 30–40%
confluent, and attached and detached cells were lysed 40 h later.
Lysate (5 ml) was incubated with substrate (200 ml, diluted 1:3),
and fluorescence detected at 360 nm/460 nm (excitation/emis-
sion) with a Synergy 2 microplate reader (Biotek; Winooski, VT).
Annexin-V FACS analysis [32]. Cells were plated in 100 mm
dishes, and treated with drugs the following day when cells were
30–40% confluent. After 40 h, cells were trypsinized, washed in
DMEM (-phenol red, +Ca2+)/5% FBS, counted, and cells (16105)
were incubated with Annexin-V-APC (5 ml) and propidium iodide
(50 mg/ml) for 159 prior to FACS analysis.
Doxorubicin Accumulation Assays [44]
Subconfluent cells were incubated with either rhodamine 123
(0.5 mg/ml) or doxorubicin (10 mM) in the presence of verapamil
(10 mM) or imatinib (40 mM) for 309, washed extensively,
incubated with verapamil or imatinib for an additional 459, and
analyzed by FACS to assess rhodamine 123 or doxorubicin
intracellular retention.
NF-kB Reporter Assays
Cells were transfected (Lipofectamine 2000, Invitrogen, Carls-
bad, CA) with 3X-NF-kB luciferase reporter and pcDNA3.1
plasmids (10:1 ratio), selected with G418 (900 mg/ml), and clones
were pooled. Cells stably expressing the reporter were plated in
triplicate, treated with doxorubicin, imatinib or the combination
for 24 h, lysed in lysis buffer (Promega; Madison, WI), lysate was
incubated with luciferin (Promega; Madison, WI) for 20, and
luminescence resulting from luciferase activity measured with the
Synergy 2 microplate reader (total light emitted, 100/well).
Nuclear fractionation assays [42]
Cells were plated in 60 mm dishes, and nuclear fractions were
isolated using the NE-PER kit (Pierce; Rockford, IL) as described
in the manufacturer’s protocol. Fraction purity was assessed by
blotting with Lamin A/C (nuclear) and a-tubulin (cytoplasm)
antibodies.
Kinase Assays [45]
Assays were performed as described previously. Briefly, cells
were serum-starved overnight, lysed in a Triton-X-100 based lysis
buffer, c-Abl and Arg immunoprecipitated, washed with a series of
stringent buffers, incubated in a kinase reaction with 32P-c-ATP,
1 mM cold ATP and GST-Crk for 409 at room temperature.
Kinase reactions were run on SDS-PAGE gels, dried, exposed to
film, and bands quantitated using a STORM phosphoimager and
ImageQuant Software (Molecular Dynamics, GE Heathcare;
Piscataway, NJK).
Statistics
Statistical analyses were performed using Sigma Stat for
Windows (Systat Software, Inc.; San Jose, CA) or the Vassar
Website. Combination Index (CI) values were calculated with
CalcuSyn software (Biosoft; Cambridge, UK) using single drug
dose response curves and combination dose response curves using
3–4 doses of each drug. For simplicity, response curves shown in
the figures demonstrate the effects of varying doxorubicin doses in
combination with one imatinib dose. Student t-tests were used to
analyze two sample comparisons; one-way ANOVA was utilized
for multiple comparisons; and single sample t-tests were performed
for comparisons against normalized controls. Two-tailed values
are reported for all tests.
Results
Imatinib reverses doxorubicin resistance
To determine whether c-Abl/Arg inhibition prevents resistance
to doxorubicin, we treated cancer cells expressing highly activated
forms of c-Abl/Arg (assessed by in vitro kinase assay and
phosphorylation of substrates, Crk/CrkL) [31,33], with the c-
Abl/Arg inhibitors, imatinib or nilotinib, alone or in combination
with doxorubicin, and measured cell viability using the CellTiter-
Glo assay, which quantitates ATP, a measure of metabolically
active cells [42,43]. Imatinib alone had a modest effect on cell
viability; however, imatinib sensitized cancer cells to doxorubicin,
shifting the curves to the left and reducing the IC50s (Figure 1A,B
and S2A,B). CalcuSyn software was utilized to calculate combi-
nation indices (CI), which indicate whether the effect of the two
drugs together is greater than either alone using the dose response
curves for each drug and the combination [42]. CI values less than
one denote drug synergism, values equal to one signify additivity,
and values greater than one indicate antagonism. Doxorubicin and
imatinib synergistically inhibited the viability of 435s/M14 and
WM3248 melanoma cells and BT-549 triple-negative (ER2, PR2,
HER-22) breast cancer cells, and inhibited the viability of MDA-
MB-468 triple-negative breast cancer cells in an additive manner
(Figure 1C and S2C). A dose of 10 mM imatinib was used for these
studies because this physiologically relevant dose is required to
effectively inhibit c-Abl/Arg kinase activities [31]. Moreover,
nilotinib, a second generation inhibitor that is more specific for c-
Abl/Arg [46], was highly synergistic with doxorubicin (Figure 1C
and S2D). Low doses of doxorubicin had little effect on c-Abl/Arg
activity (Figure 1B,C; assessed by measuring phosphorylation of
endogenous substrates, Crk/CrkL [33]), whereas higher doses
activated c-Abl/Arg (1 mM, Figure 1A). None of the cell lines
examined express PDGFRa,b, or c-Kit, other imatinib/nilotinib
targets, except MDA-MB-468 (c-Kit) [31,33]. As expected,
melanoma cells were intrinsically more resistant to doxorubicin
than breast cancer cells (435s/M14, IC50 = 0.41 mM; WM3248,
IC50 = 0.41 mM; BT-549, IC50 = 0.066 mM; MDA-MB-468,
IC50 = 0.1 mM); however, imatinib sensitized both cell types to
doxorubicin (Figure 1A,B and S2A,B). Doxorubicin is considered
front-line therapy for ‘‘triple-negative’’ breast cancers (ER2, PR2,
Her-22; e.g. BT-549) [2]; however, doxorubicin is not used to
treat melanoma due to intrinsic resistance. Here, we demonstrate
that addition of nilotinib to a doxorubicin regimen can convert
more resistant melanoma cells (IC50 = 0.41 mM) into cells that
have a similar doxorubicin sensitivity as MDA-MB-468 breast
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Figure 1. c-Abl/Arg inhibitors reverse doxorubicin resistance. (A) 435s/M14 melanoma and (B) BT-549 breast cancer cells were treated with
doxorubicin/imatinib (72 h), and viability assessed by CellTiter-Glo. Mean6SEM for 3 independent experiments (left). Representative dose response
curve (right). (C,F) Graphical representation of combination indices obtained with CalcuSyn software using dose response curves for each drug alone
and in combination. .1-antagonism; = 1-additive; ,1-synergism. Graphs are representative of 3 independent experiments. (D) Cells stably
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cancer cells (435s/M14-nilotinib+doxorubicin. IC50 = 0.16 mM vs.
MDA-MB-468-doxorubicin, IC50 = 0.1 mM; Figure S2B,D).
Next, we tested whether c-Abl/Arg are the targets of imatinib
during doxorubicin-mediated sensitization. Unfortunately, trans-
fection of cells with c-Abl/Arg-specific siRNAs reduced cell
proliferation [32,33], decreasing the effectiveness of doxorubicin,
which targets proliferating cells. Furthermore, it was not possible
to transfect siRNAs after doxorubicin treatment, as this resulted in
inefficient knockdown (data not shown). Moreover, cells stably
expressing c-Abl/Arg shRNAs could not be obtained, likely due to
the requirement of c-Abl/Arg for cell growth (data not shown).
Therefore, we utilized an alternative strategy which involved
expressing imatinib-resistant mutant forms of c-Abl and Arg (c-
AblT315I, ArgT315I, abbreviated AblT/ArgT), and determining
whether their expression rescues imatinib-mediated chemosensiti-
zation. Expression of the mutant forms prevented imatinib from
inhibiting c-Abl/Arg activity (assessed by blotting with an antibody
to the c-Abl/Arg phosphorylation sites on substrates, Crk and
CrkL; Figure S2E). Significantly, expression of imatinib-resistant
forms of c-Abl and Arg prevented imatinib-mediated sensitization
to doxorubicin (Figure 1D), whereas expression of either c-
AblT315I or ArgT315I alone only partially abrogated imatinib-
mediated sensitization (data not shown). These data indicate that
imatinib-mediated reversal of doxorubicin resistance is due, in
large part, to inhibition of c-Abl and Arg.
Cells that acquire high-level doxorubicin resistance are
extremely sensitive to imatinib/nilotinib in the presence
of doxorubicin
Although chemotherapeutic agents sometimes kill the majority
of cells, residual, highly resistant cells often remain, which are very
aggressive and metastatic. In order to mimic outgrowth of highly
resistant, metastatic cells following treatment with chemothera-
peutic agents, we cultured 435s/M14 melanoma cells with
increasing concentrations of doxorubicin over the course of 8
months (435s/M14-DR). 435s/M14-DR cells were highly resistant
to doxorubicin (1 mM reduced viability by 15% as compared to
80% in parental cells; IC50&2 mM), and continued to express
highly active c-Abl/Arg (Figure 1E and S3A,B). Significantly,
imatinib and nilotinib dramatically sensitized highly resistant cells
to doxorubicin (Figure 1E,F and S3B,C). These data indicate that
c-Abl/Arg inhibitors not only are involved in reversing intrinsic
doxorubicin resistance, but also abrogate acquired resistance.
Imatinib reverses doxorubicin resistance by preventing
G2/M arrest and inhibiting apoptosis
Since viability is a balance of proliferation and apoptosis, we
tested whether imatinib prevents chemoresistance by potentiating
the anti-proliferative and/or pro-apoptotic effects of doxorubicin.
Using tritiated–thymidine assays to assess cell proliferation, we
show that imatinib alone inhibited proliferation of cells with
intrinsic and acquired resistance, and addition of low doses of
doxorubicin completely blocked cell proliferation (Figure 2A–C
and S4A–D). To determine the mechanism by which imatinib
synergizes with doxorubicin to prevent cell proliferation, BrdU/PI
cell cycle analyses were performed on treated, asynchronously
growing cells. Low dose doxorubicin treatment of parental cells
resulted in a dose-dependent accumulation of cells in G2/M, and
imatinib treatment dramatically potentiated the G2/M arrest
(Figure 2D and S4E-left). In cells that acquired high-level
doxorubicin resistance, doxorubicin alone had little effect on the
cell cycle; however, addition of imatinib induced a dramatic
blockade of cells in G2/M, using extremely low doxorubicin doses
(30–60 nM; Figure 2E and S4E-right), indicating that imatinib
reverses doxorubicin resistance, in part, by enhancing doxorubi-
cin-mediated G2/M arrest.
To examine whether imatinib abrogates chemoresistance by
potentiating doxorubicin-mediated apoptosis, we assessed caspase-
3/7 activity, PARP cleavage, and/or Annexin V staining in cells
treated with higher doses of doxorubicin alone or in combination
with imatinib. Imatinib alone modestly, but significantly, induced
caspase-3/7 activity or PARP cleavage in all cell lines tested
(Figure 3A,B and S4F). Significantly, imatinib potentiated
doxorubicin-induced caspase-3/7 activity, PARP cleavage, and/
or Annexin V staining in 435s/M14, BT-549 and WM3248 cell
lines, but not in MDA-MB-468 (Figure 3A–D and S4F,G; data not
shown). These data indicate that imatinib prevents intrinsic
doxorubicin resistance in 435s/M14, BT-549, and WM3248 cells
by inducing cell cycle arrest (at low doxorubicin doses) and
abrogating survival (at higher doses). Conversely, in MDA-MB-
468 cells, imatinib only inhibited proliferation and did not
potentiate apoptosis, which explains why the effects of imatinib
on viability were additive rather than synergistic. Interestingly, in
cells that acquired high-level doxorubicin resistance, doxorubicin
alone did not induce apoptosis; however, the addition of imatinib
dramatically activated caspase-3/7 and induced PARP cleavage
(Figure 3E,F). In conclusion, imatinib reverses both intrinsic and
acquired resistance to doxorubicin by potentiating doxorubicin-
mediated G2/M arrest and apoptosis.
c-Abl contributes to upregulation of ABCB1, and ABCB1
overexpression promotes acquired doxorubicin
resistance
Chemoresistance can result from activation of cell proliferation/
survival pathways and/or can be mediated by overexpression of
multi-drug resistance (ABC) transporters, which efflux the
chemotherapeutic agents [7]. To determine whether imatinib
prevents doxorubicin intracellular accumulation, cells were treated
with vehicle/imatinib for 72 h, washed, incubated with doxoru-
bicin for 309 in the absence of imatinib, and intracellular
doxorubicin assessed in living cells. Doxorubicin possesses intrinsic
fluorescence, which allows for its detection by flow cytometry. Less
intracellular doxorubicin was observed in 435s/M14-DR cells as
compared to parental cells (Figure 4A). Moreover, intracellular
doxorubicin levels in parental cells were only slightly affected by
treatment with imatinib, whereas in 435s/M14-DR cells, much
more doxorubicin was retained in the cells following imatinib
treatment, as evidenced by the curve shifting to the right
(Figure 4A). These data indicate that imatinib-mediated chemo-
sensitization likely occurs independent of an ABC transporter in
parental cells, whereas in cells that acquire high-level resistance,
chemosensitization likely involves inhibition of ABC transporter
function. In order to identify the transporter involved in
doxorubicin efflux in 435s/M14-DR cells, we tested whether the
expressing imatinib-resistant mutant Arg (ArgT) were transiently transfected with imatinib-resistant c-Abl (c-AblT), treated with doxorubicin/imatinib
(48 h), and viability assessed. Representative experiment (left). Mean6SEM of 3 independent experiments: imatinib alone (right, top) and
imatinib+doxorubicin (right, bottom). (E,F) Parental (E) and acquired doxorubicin-resistant (F) cells were drug-treated (72 h), and viability assessed.
Experiments were performed $3 times, and representative dose response curves are shown. Mean6SEM for 3 independent experiments is shown in
Figure S3B. For all subfigures, some error bars are too small to visualize. *p,0.05, **p,0.01, ***p,0.001 (see methods).
doi:10.1371/journal.pone.0055509.g001
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Figure 2. Imatinib abrogates doxorubicin resistance, in part, by potentiating doxorubicin-mediated G2/M arrest. (A–C) Proliferation
was assessed in treated cells (72 h) by tritiated thymidine assay. Representative dose response curves (A, B, left) and Mean6SEM for 3 independent
experiments (A–C, right). Some error bars are too small to visualize. (C) CI values: Dox(0.015 mM)+imatinib(2 mM)=0.960.14; Dox(0.015 mM)+i-
matinib(5 mM) = 0.6760.07; Dox(0.015 mM)+imatinib(10 mM) = 0.560.06; Dox(0.03 mM)+imatinib(2 mM) = 0.860.11; Dox(0.03 mM)+imati-
nib(5 mM)= 0.560.13; Dox(0.03 mM)+imatinib(10 mM)=0.3660.18. (D, E) Asynchronous drug-treated cells (72 h) were analyzed by FACS. Experiments
were performed $3 times, and representative cell cycle distributions are shown. Mean6SEM for 3 independent experiments is shown in Figure S4E.
**p#0.01, ***p,0.001 (see methods).
doi:10.1371/journal.pone.0055509.g002
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cells also are resistant to other chemotherapeutic agents from other
chemotherapeutic classes. Interestingly, 435s/M14-DR cells were
highly resistant to paclitaxel, and this resistance was abrogated by
imatinib treatment (Figure 4B). However, 435s/M14-DR cells
remained sensitive to camptothecin, 5-fluorouracil, and cisplatin
(Figure 4B). Candidate transporters that efflux doxorubicin and
paclitaxel include ABCB1, ABCG2, and ABCC1 [7]. Interesting-
ly, 435s/M14-DR cells expressed dramatically elevated levels of
ABCB1 protein in contrast to parental cells, which did not express
ABCB1, whereas ABCC1 and ABCG2 were expressed at low
levels in both cell lines (Figure 4C). Treatment of 435s/M14-DR
cells with imatinib or nilotinib or transfection of cells with c-Abl
but not Arg siRNA, partially inhibited ABCB1 expression
(Figure 4D), indicating that c-Abl contributes to ABCB1
upregulation following acquired resistance to doxorubicin. Since
prior imatinib treatment prevented doxorubicin from being
effluxed from 435s/M14-DR cells (Figure 4A) even though
imatinib was not present during the assay (i.e., during incubation
with doxorubicin), and imatinib binding to ABC transporters is
known to be a reversible process [47], these data indicate that
imatinib increases intracellular doxorubicin retention in 435s/
M14-DR cells, in part, by decreasing ABCB1 expression.
Imatinib sensitizes cells that acquire high-level
doxorubicin resistance to doxorubicin, in part, by
inhibiting ABCB1 function
Imatinib has been shown to be a substrate and/or inhibitor of
ABCB1 and ABCG2 in leukemic cells [47–51]. Therefore,
Figure 3. Imatinib reverses doxorubicin resistance by inhibiting cell survival. Caspase-3/7 activity (A,B,E), Annexin V staining (C), or PARP
cleavage (D,F) were assessed in lysates from attached and detached treated cells (40 h unless otherwise indicated). Mean6SEM of 3 experiments
(A,B,E) or representative of 3 independent experiments (C,D,F). Some error bars (A,B,E) are too small to visualize. *p,0.05, **p#0.01, ***p,0.001
(see methods).
doi:10.1371/journal.pone.0055509.g003
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Figure 4. c-Abl inhibition decreases ABCB1 expression and activity. (A) Cells were treated with imatinib (72 h), washed, treated with
doxorubicin (309) in the absence of imatinib, and intracellular doxorubicin fluorescence assessed by FACS. The experiment was performed$3 times; a
representative experiment is shown. (B) Cells were drug- treated (72 h), and viability was assessed. Graph is representative of 3 independent
experiments. Some error bars are too small to visualize. PTX =paclitaxel (30 nM), Cam= camptothecin (1 mM), Cis = cisplatin (20 mM), 5-FU= 5-
fluorouracil (500 mM). (C,D) Western blot analysis. Lysate from MCF-7 cells transfected with ABCC1 served as a positive control for ABCC1 expression.
Blots are representative of$3 independent experiments. (D) Cells were imatinib or nilotinib-treated (48 h, left) or transfected with siRNAs (right), and
lysates blotted with the indicated antibodies. Mean6SEM from 3 independent experiments (below). (E) siRNA-transfected cells were treated with
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imatinib also may sensitize highly resistant cells to doxorubicin by
directly inhibiting drug efflux. To confirm that ABCB1 mediates
doxorubicin efflux and to ascertain whether imatinib specifically
interferes with ABCB1-mediated efflux of doxorubicin, we
performed doxorubicin accumulation assays in the absence or
presence of imatinib, ABCB1 siRNA, or verapamil (ABCB1
inhibitor), and measured doxorubicin intracellular fluorescence.
Silencing ABCB1 increased doxorubicin retention (Figure 4E),
and imatinib promoted doxorubicin and rhodamine 123 (a
ABCB1 substrate) accumulation, to a similar extent as verapamil
(ABCB1 inhibitor; Figure 4F,G). Taken together, these studies
demonstrate that imatinib directly inhibits ABCB1-mediated
doxorubicin efflux in cells that acquire high-level doxorubicin
resistance, in addition to preventing ABCB1 upregulation. Next,
we assessed the functional impact of ABCB1 expression in cells
that acquired doxorubicin resistance by assessing the effect of
silencing/inhibiting ABCB1 on cell viability. Silencing ABCB1 or
verapamil treatment dramatically sensitized resistant cells to
doxorubicin (Figure 5A,B). However, imatinib further decreased
the viability of cells treated with verapamil/doxorubicin or
ABCB1 siRNA/doxorubicin (Figure 5A,B), indicating that inhibi-
tion of ABCB1 is not the only mechanism by which imatinib
sensitizes acquired resistant cells to doxorubicin. In addition,
unlike rhodamine 123, in the absence of transporter inhibitors,
doxorubicin is not completely effluxed from 435s/M14-DR cells
(Figure 4G vs. Figure 4F). Therefore, since 435s/M14-DR cells
continue to retain some doxorubicin, but are resistant to its effects,
this indicates that transporter-independent pathways also contrib-
ute to acquired doxorubicin resistance.
Imatinib potentiates doxorubicin-induced apoptosis by
inhibiting STAT3-dependent survival pathways
Since ABC transporters are not involved in intrinsic resistance,
and transporter-independent pathways contribute to acquired
resistance, we set out to identify signaling pathways by which
imatinib prevents survival during doxorubicin treatment. Previ-
ously, we showed that c-Abl/Arg promote phosphorylation of the
STAT3 transcription factor (Y705) in a variety of cancer cell lines
[32,33]. STAT3 drives cancer cell proliferation, survival, invasion,
and metastasis, and also has been implicated in chemoresistance;
thus, c-Abl/Arg may drive doxorubicin resistance by activating
STAT3 [12,32,52]. In the absence of doxorubicin, stable
expression of a constitutively active form of STAT3 (STAT3C)
prevented the modest imatinib-mediated activation of caspase-3/
7, indicating that imatinib prevents cancer cell survival by
inhibiting activation of STAT3 (Figure 6A). Next, we tested
whether STAT3 dephosphorylation is required for imatinib to
reverse doxorubicin resistance. Doxorubicin inhibited STAT3
phosphorylation in parental cells, which was potentiated by
imatinib (Figure 6B-left). Interestingly, doxorubicin also inhibited
STAT3 phosphorylation in cells that acquired doxorubicin
resistance (albeit to a lower extent; Figure 6B-right) even though
doxorubicin is efficiently effluxed by ABCB1 in these cells
(Figure 4). Expression of STAT3C partially prevented imatinib
from potentiating doxorubicin-mediated inhibition of viability,
doxorubicin (309), washed, and intracellular doxorubicin fluorescence assessed. Graph is representative of 3 independent experiments. Representative
Western blot (right). (F, G) Cells were treated with either doxorubicin (F) or rhodamine 123 (G) in the presence of the ABCB1 inhibitor, verapamil, or
imatinib for 309, washed, and incubated with verapamil or imatinib for an additional 459, and rhodamine 123 or doxorubicin intracellular fluorescence
assessed by FACS. Graphs are representative of 3 independent experiments. *p,0.05, **p#0.01, ***p,0.001 (see methods). n.s. = not significant.
doi:10.1371/journal.pone.0055509.g004
Figure 5. Resistance to doxorubicin occurs via ABCB1-dependent and ABCB1-independent mechanisms. (A, B) ABCB1 was inhibited
with verapamil (A) or silenced with siRNA (B), cells were treated with imatinib (10 mM) and/or doxorubicin (0.5 mM) for 72 h, and cell viability
assessed. Mean6SEM from 3 independent experiments. (A) Dox+imatinib, CI = 0.6660.19; Dox+verapamil, CI = 0.1460.04; Dox+imatinib+verapamil,
CI = 0.4760.5. Representative Western blot (right). Some error bars are too small to visualize.
doi:10.1371/journal.pone.0055509.g005
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proliferation, and cell cycle progression (Figure S5), and
completely blocked the ability of imatinib to cooperate with
doxorubicin to induce PARP and caspase-3 cleavage (Figure 6C).
Furthermore, silencing STAT3 potentiated doxorubicin-induced
PARP and caspase-3 cleavage similar to the effects observed with
imatinib (Figure 6D). Taken together, these data indicate that
doxorubicin-mediated inhibition of STAT3 phosphorylation is
required for doxorubicin to kill cancer cells, and imatinib reverses
doxorubicin resistance by preventing STAT3 phosphorylation.
Imatinib promotes doxorubicin-induced NF-kB-mediated
repression of anti-apoptotic genes
NF-kB promotes oncogenesis, increasing proliferation, survival,
invasion, and metastasis by promoting the transcription of pro-
proliferative, pro-invasive, and anti-apoptotic genes, and STAT3
promotes NF-kB transcriptional activity [14,53]. Since c-Abl/Arg
activate STAT3, we investigated whether c-Abl/Arg regulate NF-
kB signaling. In the absence of doxorubicin, silencing or inhibiting
c-Abl or Arg inhibited p65 nuclear localization, and decreased
basal and TNF-a-induced NF-kB transcriptional activity (Figure
S6A–C), indicating that c-Abl/Arg activate NF-kB signaling in
cancer cells. To determine whether imatinib prevents survival in
response to doxorubicin treatment by affecting NF-kB signaling,
we assessed p65 nuclear localization and phosphorylation follow-
ing imatinib/doxorubicin treatment. p65 phosphorylation regu-
lates its acetylation and nuclear localization/retention [53,54].
Surprisingly, in parental cells, doxorubicin treatment increased
p65 (S536) phosphorylation and dramatically induced its nuclear
localization, which was potentiated by imatinib, and doxorubicin
and imatinib cooperated to decrease NF-kB transcriptional
activity (Figure 7A,B-top). Therefore, NF-kB nuclear localization
induced by doxorubicin correlated with decreased transcriptional
activity, which is consistent with doxorubicin converting NF-kB
into a transcriptional repressor [16,19]. The modest effects we
observed on transcriptional activity are in the same range as those
previously reported [16]. Furthermore, imatinib enhanced NF-kB
repressive activity, indicating that it acts to potentiate doxorubicin-
mediated conversion of NF-kB into a transcriptional repressor. In
contrast, in cells that acquired high-level doxorubicin resistance,
doxorubicin increased NF-kB transcriptional activity, which was
abrogated by imatinib (Figure 7B-bottom). Thus, in these cells,
doxorubicin does not convert NF-kB into a repressor but instead
promotes NF-kB transcriptional activity, and imatinib inhibits
doxorubicin-mediated NF-kB activation. These data are signifi-
cant as they indicate that NF-kB-mediated signaling mechanisms
underlying doxorubicin resistance are not identical for cells with
intrinsic vs. acquired resistance.
To confirm that NF-kB indeed acts as a repressor following
doxorubicin+imatinib treatment in parental cells, we examined
expression of NF-kB targets, such as those involved in inhibiting
apoptosis (cIAP, XIAP). Many cancers overexpress cIAP1 and
XIAP, and are addicted to their expression [15]. In parental cells,
doxorubicin inhibited cIAP1/XIAP expression, and imatinib
potentiated this inhibition (Figure 7C and S6D). In contrast, in
cells that acquired high-level resistance, doxorubicin treatment
had little effect on cIAP or XIAP expression (Figure 7D and S6E);
however, addition of imatinib dramatically reduced cIAP1/XIAP
expression (Figure 7D and S5E). These data are significant
because they demonstrate that imatinib not only prevents NF-kB
activation following doxorubicin treatment in cells that acquired
doxorubicin resistance, but also converts NF-kB into a repressor
that inhibits expression of cIAP1/XIAP. Significantly, silencing
p65, in parental cells, reduced doxorubicin-mediated PARP and
caspase-3 cleavage, and partially inhibited the potentiation
induced by imatinib treatment (Figure 7E and S6F), which
indicates that imatinib reverses doxorubicin resistance, in part, by
inducing p65 nuclear translocation.
Imatinib potentiates doxorubicin-mediated NF-kB
nuclear localization and inhibition of NF-kB target
expression by inhibiting activation of STAT3
Since STAT3 and NF-kB bind and cooperate to regulate
transcription [52], c-Abl/Arg activate STAT3, and constitutive
STAT3 activation prevents imatinib from reversing doxorubicin
resistance (Figure 6C), we tested whether imatinib induces NF-kB-
mediated apoptosis by inhibiting STAT3-dependent pathways.
Significantly, silencing STAT3 potentiated doxorubicin-induced
p65 nuclear localization, similar to imatinib (Figure 8A), and
STAT3C expression prevented the imatinib-mediated increase in
nuclear p65 (Figure 8B). Moreover, expression of STAT3C
partially prevented imatinib from potentiating doxorubicin-medi-
ated inhibition of cIAP1/XIAP expression (Figure 8C). Taken
together, these data indicate that imatinib promotes p65 nuclear
localization and inhibits NF-kB target expression by at least, in
part, by inhibiting STAT3 activation.
Imatinib abrogates doxorubicin resistance, in part, by
preventing activation of a STAT3-dependent HSP27/p38/
Akt pathway
Expression of constitutively active STAT3 (STAT3C) com-
pletely prevented imatinib from increasing apoptosis following
doxorubicin treatment (Figure 6C); however, silencing p65 only
partially prevented imatinib from increasing doxorubicin-induced
apoptosis (Figure S6F). These data indicate that imatinib reverses
doxorubicin resistance via more than one STAT3-dependent
pathway. PI3K/Akt are major mediators of cancer cell survival,
and play a role in chemoresistance [23,24]. Doxorubicin induced
Akt phosphorylation in parental and highly resistant cells, and this
was inhibited by addition of imatinib (Figure 9A and S7A,B). In
neuronal cells and neutrophils, activation of a HSP27/p38/MK2
pathway mediates S473 phosphorylation following DNA damage/
cell stress [26,28,29]. To test whether doxorubicin activates Akt in
melanoma cells via a HSP27/p38 pathway, we examined p38
phosphorylation and HSP27 expression in doxorubicin/imatinib-
treated cells. Indeed, doxorubicin induced expression of HSP27
and phosphorylation of p38, and imatinib dramatically inhibited
HSP27/p-p38 induction (Figure 9A and S7A). Similar to imatinib,
silencing STAT3 reduced Akt and p38 phosphorylation and
HSP27 expression (Figure 9B, and S7C). Furthermore, expression
of STAT3C prevented imatinib from reducing HSP27, phospho-
p38, and phospho-Akt expression in the presence of doxorubicin
(Figure 9C), indicating that imatinib-mediated inhibition of the
HSP27/p38/Akt pathway involves inhibition of STAT3. More-
over, expression of a constitutively active p110a catalytic subunit
of PI3K (E545K), which activates Akt (Figure 9D, bottom right),
partially prevented imatinib-dependent potentiation of doxorubi-
cin-induced PARP cleavage (Figure 9D). Thus, this is the first
demonstration that imatinib prevents activation of a novel
STAT3/HSP27/p38/Akt pathway, and that a HSP27/p38
pathway is involved in activating Akt during doxorubicin
resistance. In summary, imatinib reverses intrinsic doxorubicin
resistance by preventing STAT3 phosphorylation, which inhibits a
HSP27/p38/Akt survival pathway and promotes activation of an
NF-kB-mediated pro-apoptotic pathway (Figure 10).
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Discussion
Here, we show that imatinib prevents intrinsic and acquired
resistance to doxorubicin by: 1) inhibiting c-Abl/Arg activation; 2)
promoting doxorubicin-mediated cell cycle arrest at G2/M; 3)
inhibiting activation of a STAT3-dependent HSP27/p38/Akt
survival pathway; 4) promoting NF-kB-mediated inhibition of
anti-apoptotic protein expression in a STAT3-dependent manner;
and 5) inhibiting upregulation of the drug transporter, ABCB1,
Figure 6. Imatinib promotes apoptosis in response to doxorubicin by inhibiting STAT3-dependent survival pathways. (A) 435s/M14
cells, stably transfected with pcDNA or STAT3C, were treated with imatinib (40 h), and caspase 3/7 activity assessed in lysate from attached/detached
cells. Graph is Mean6SEM from 3 independent experiments. Representative Western blot (above). (B) Parental (435s/M14) and acquired doxorubicin-
resistant (435s/M14-DR) cells were drug-treated (40 h), and lysates from attached/detached cells were blotted with antibodies. Graphs are
Mean6SEM from 3 independent experiments. (C) Western blots of lysates from 435s/M14 cells expressing pcDNA or STAT3C, treated with imatinib/
doxorubicin (40 h). Graphs are Mean6SEM from 3 independent experiments. (D) Lysates from drug-treated (40 h), attached/detatched 435s/M14
cells transfected with STAT3 siRNA were blotted. Graphs are Mean6SEM from 3 independent experiments. For all subfigures, some error bars are too
small to visualize. *p,0.05, **p#0.01, ***p,0.001 (see methods).
doi:10.1371/journal.pone.0055509.g006
Imatinib Reverses Doxorubicin Resistance
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e55509
Figure 7. Imatinib abrogates doxorubicin resistance, in part, by increasing p65 nuclear translocation, and inhibiting expression of
NF-kB targets. (A) Nuclear lysates from doxorubin (0.5 mM-top; 1 mM-bottom)/imatinib (10 mM)-treated 435s/M14 cells (8 h) were blotted. Graphs
are Mean6SEM from 3 independent experiments. (B) Parental (435s/M14) and doxorubicin-resistant (435s/M14-DR) cells, stably expressing a 3X-NF-
kB-luciferase reporter, were drug treated (8 h), and luciferase activity assessed. Graphs are Mean6SEM from 3 independent experiments. (C, D)
Lysates from treated cells were analyzed by Western blot (40 h treatment). Representative blots are shown. Mean6SEM from 3 independent
experiments is shown in Figure S6D,E. (E) 435s/M14 cells transfected with p65 siRNA were drug-treated (8 h), and PARP and caspase-3 cleavage
assessed. Graphs are Mean6SEM from 3 independent experiments. *p,0.05, **p#0.01 (see methods).
doi:10.1371/journal.pone.0055509.g007
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and directly inhibiting ABCB1 function (acquired resistance).
These data are novel and significant because the upstream
mechanisms that govern NF-kB-mediated transcriptional repres-
sion have not previously been identified. Furthermore, this is the
first demonstration that HSP27/p38/Akt promote doxorubicin
Figure 8. Imatinib promotes p65 nuclear translocation and inhibits NF-kB target expression in a STAT3-dependent manner. (A)
435s/M14 cells, transfected with STAT3 siRNA, were drug treated (8 h), and nuclear fractions analyzed by Western blot. Graph is Mean6SEM from 3
independent experiments. (B) 435s/M14 cells stably expressing pcDNA or STAT3C were drug treated (8 h), and nuclear fractions analyzed by Western
blot. Graph is Mean6SEM of 3 independent experiments. (C) Lysates from drug-treated pcDNA and STAT3C-expressing cells (40 h), were analyzed by
Western blot. Graphs are Mean6SEM from 3 independent experiments. For all subfigures, some error bars are too small to visualize. *p,0.05,
**p#0.01 (see methods).
doi:10.1371/journal.pone.0055509.g008
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resistance in melanoma cells, and we are the first to show that
STAT3 is involved in activation of this pathway.
The role of NF-kB in doxorubicin-induced cell death is
controversial as doxorubicin-mediated activation of NF-kB
prevents cell death in some cell types, while in other cells,
doxorubicin-mediated activation of NF-kB promotes apoptosis by
repressing expression of anti-apoptotic genes [16–20]. In addition,
the mechanism by which anthracyclines convert NF-kB into a
repressor also is under debate. Barker and colleagues showed that
doxorubicin induces p65 nuclear localization and DNA binding of
a non-acetylated/non-phosphorylated form of p65, which inhibits
NF-kB transcriptional activity in a histone deacetylase (HDAC)-
independent manner [19]. In contrast, Perkins and colleagues
demonstrated that anthracyclines induce phosphorylation/acety-
Figure 9. Imatinib abrogates doxorubicin resistance, in part, by preventing activation of a STAT3/HSP27/p38/Akt survival pathway.
(A, B) 435s/M14 cells were treated with imatinib (10 mM) (A) or transfected with STAT3 siRNA (B), treated with doxorubicin (p38, Akt, 0.5 mM; HSP27,
1 mM) for 40 h, and lysate from attached/detached cells blotted with antibodies. Experiments were performed 3 times; representative blots are
shown. Mean6SEM for 3 experiments is shown in Figure S7A. (C) 435s/M14 cells expressing pcDNA or STAT3C were drug treated (40 h), and lysate
from attached/detached cells were blotted with antibodies. Graphs are Mean6SEM from 3 independent experiments (bottom). (D) 435s/M14 cells
expressing vector or constitutively active PI3K (E545K) were drug-treated (8 h) and PARP cleavage assessed. Graph is Mean6SEM from 3 independent
experiments. Representative Western blot (right). For all subfigures, some error bars are too small to visualize. *p,0.05, **p#0.01, ***p,0.001 (see
methods).
doi:10.1371/journal.pone.0055509.g009
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lation and nuclear translocation of p65 in mouse embryo
fibroblasts, and p65 represses gene expression by recruiting
HDACs to gene targets [16]. In addition, Yu and colleagues
showed that p65 acetylation is required for its nuclear retention,
which is inconsistent with data from Barker and colleagues who
demonstrate that non-phosphorylated/non-acetylated p65 binds
DNA, and thus, is in the nucleus [19,53]. Here, we show that
doxorubicin induces p65 phosphorylation and nuclear transloca-
tion, which is enhanced by imatinib treatment or silencing
STAT3, and correlates with decreased NF-kB transcriptional
activity and downregulation of NF-kB targets. Thus, STAT3
activation inhibits doxorubicin-mediated p65 nuclear localization,
which is contrary to data obtained in untreated cancer cells
indicating that STAT3 promotes p65 nuclear retention [53].
Thus, our data indicate that STAT3 likely has an opposite role in
regulating p65 nuclear localization in response to stimuli that
convert NF-kB into a repressor [53].
Our data are consistent with Perkins and colleagues who
demonstrate that doxorubicin increases NF-kB phosphorylation/
acetylation/DNA binding but this activated NF-kB represses
rather than activates transcription [16]. We provide additional
data aimed at elucidating the mechanism by demonstrating that
imatinib targets (likely c-Abl/Arg) and STAT3 regulate NF-kB
function following doxorubicin treatment. It is possible that c-Abl/
Arg and STAT3 prevent conversion of NF-kB into a repressor by
promoting recruitment of histone acetyltransferases (HATs) to
p65/p50-DNA complexes whereas inhibition of c-Abl/Arg or
STAT3 promotes recruitment of histone deacetylases (HDACs)
[16]. Interestingly, in cells that have acquired high-level resistance,
doxorubicin increases NF-kB transcriptional activity, and NF-kB
does not appear to function as a repressor. This may be because
doxorubicin only modestly inhibits STAT3 phosphorylation, and
thus, HAT recruitment may be dominant over HDAC recruit-
ment in these cells. Addition of imatinib dramatically inhibits
STAT3 and leads to repression of NF-kB targets (cIAP1, XIAP),
perhaps by facilitating HDAC/p65 rather than HAT/p65
complexes. In either event, our data are highly significant because
they demonstrate that imatinib converts a master survival
regulator, NF-kB, from a pro-survival into a pro-apoptotic factor,
thereby rendering a conventional chemotherapeutic agent more
effective for treating metastatic disease. These data are extremely
important because they indicate that NF-kB inhibitors may be
ineffective in sensitizing tumors containing activated c-Abl/Arg to
anthracyclines, and instead may antagonize anthracycline-induced
apoptosis.
In addition to inhibiting survival signaling, we also demonstrate
that c-Abl/Arg inhibitors partially prevent ABCB1 upregulation in
cells that acquire doxorubicin resistance, and also directly inhibit
ABCB1 function. c-Abl/Arg inhibitors have been identified as
substrates of drug transporters in other cell types [7,55]; however,
this is the first demonstration that they inhibit ABCB1 in
melanoma cells. In addition, we are the first to show that c-Abl
promotes expression of an ABC transporter. ABC transporter
upregulation has been shown to occur via a variety of pathways
including FOXO3a and PI3K/Akt, NF-kB, HSP27, and ERK
pathways [8–10]; ongoing experiments are aimed at identifying
the mechanism of ABCB1 upregulation. ABCB1 also is a
transporter for other chemotherapeutic agents, such as paclitaxel,
vinblastine, vincristine, etoposide as well as for the selective
estrogen receptor modulator (SERM), tamoxifen [7]. Thus, c-Abl/
Arg inhibitors are likely to reverse resistance to many of these
agents as well. In support of this hypothesis, we demonstrate that
c-Abl/Arg inhibitors sensitize melanoma cells to paclitaxel, and
Wang and colleagues showed that c-Abl/Arg inhibition sensitizes
breast cancer cells to tamoxifen [56].
Doxorubicin is utilized to treat many cancers including triple-
negative breast cancer; however, resistance and toxicity limit its
effectiveness [2,5]. Anthracyclines are not routinely used to treat
metastatic melanoma due to intrinsic resistance; however, current
treatment regimens (dacarbazine-DTIC or temozolamide-TMZ)
are also ineffective (,5% success rate), and newer biological agents
only extend survival by 4 months [57–59]. Our data demonstrate
that c-Abl/Arg inhibitors (imatinib, nilotinib) are effective in
reversing intrinsic and acquired doxorubicin resistance, thereby
increasing doxorubicin effectiveness at lower doses. These data
have important clinical ramifications as they indicate that Abl
inhibitor/doxorubicin combinations may be effective for treating
cancers driven by activated c-Abl and Arg.
Supporting Information
Figure S1 Genetic analysis of the BT-549 cell line. DNA
profile STR testing (DNA Safe) was performed by Genetic Testing
Laboratory Inc. (GTL; Los Cruces, NM). The analysis revealed
complete identity at all loci with the BT-549 breast cancer cell line
(ATCC; Manassas, Va).
(PDF)
Figure S2 c-Abl/Arg inhibitors reverses intrinsic doxo-
rubicin resistance. (A) WM3248 melanoma cells and (B)
MDA-MB-468 breast cancer cells were treated with doxorubicin/
imatinib (72 h) and viability assessed. Mean6SEM for 3
independent experiments (left) and representative dose response
curves (right). (C) Graphical representation of combination indices
obtained with CalcuSyn software (.1-antagonism; = 1-additive;
,1-synergism). (D) Parental (435s/M14) cells were treated with
nilotinib/doxorubicin (72 h), and viability assessed. Mean6SEM
for 3 independent experiments (left). Dose response curve is a
representative experiment (right). (E) 293T cells expressing
imatinib-resistant c-Abl (T) and Arg (T) were treated with imatinib
(72 h) and blotted with antibodies. For all subfigures, IC50s
represent Mean6SEM for 3 independent experiments; some error
bars are too small to visualize.. *p,0.05, ***p,0.001, using t-tests
(see methods).
(PDF)
Figure 10. Mechanisms by which imatinib abrogates intrinsic
doxorubicin resistance. Imatinib prevents activation of STAT3, which
promotes doxorubicin-mediated NF-kB phosphorylation and nuclear
translocation and NF-kB-mediated inhibition of expression of anti-
apoptotic proteins such as cIAP1/XIAP. Imatinib-mediated inhibition of
STAT3 also prevents activation of a HSP27/p38/Akt pro-survival
pathway.
doi:10.1371/journal.pone.0055509.g010
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Figure S3 c-Abl/Arg inhibition reverses acquired doxo-
rubicin resistance. (A) Parental 435s/M14 cells and their
counterpart that acquired high-level doxorubicin resistance (DR)
were serum-starved, and kinase activity assessed by in vitro kinase
assay utilizing GST-Crk as substrate, and lysates blotted with the
indicated antibodies. (B) Mean6SEM for 3 independent exper-
iments for data shown in Fig. 1E. 435s/M14-DR - Dox
(0.5 mM)+imatinib (10 mM), CI= 0.5; Dox (2 mM)+imatinib
(10 mM), CI= 0.08. (C) Viability was assessed in nilotinib/
doxorubicin-treated 435s/M14-DR cells. Mean6SEM for 3
independent experiments (left). Representative dose-response
curve (right). For all subfigures, IC50s represent Mean6SEM for
3 independent experiments. *p,0.05, ***p,0.001, using t-tests
(see methods).
(PDF)
Figure S4 c-Abl/Arg inhibition reverses doxorubicin
resistance by inhibiting proliferation and inducing
apoptosis. (A) MDA-MB-468 breast cancer and (B) WM-3248
melanoma cells were treated with doxorubicin and/or imatinib
(72 h), and proliferation assessed by tritiated thymidine assay.
Graphs shown are representative experiments. (A) MDA-MB-468
- Dox (0.005 mM)+imatinib (10 mM), CI= 1.1; Dox (0.01 mM)+i-
matinib (10 mM), CI= 0.9; (B) WM3248 - Dox (0.005 mM)+i-
matinib (10 mM), CI= 0.72; Dox (0.03 mM)+imatinib (10 mM),
CI= 0.56. (C) Graphical representation of combination indices
obtained with CalcuSyn software for data described in Fig. 2A,B
in 435s/M14 (left) and BT-549 (right) cells. Graphs are
representative of 3 independent experiments (.1-antagonism;
= 1-additive; ,1-synergism). (D) 435s/M14-DR cells were treated
with doxorubicin/imatinib (72 h), and proliferation assessed by
tritiated thymidine assay. Representative dose response curve for
data described in Fig. 2C. (E) Graphical representation of cells in
G2/M phase for data shown in Fig. 2D,E. Mean6SEM from 3
independent experiments. (F,G) Cells were treated with doxoru-
bicin/imatinib (40 h), and lysate from attached and detached cells
was assessed for caspase-3/7 activity (F) or PARP cleavage (G).
Representative experiments (from 3 independent experiments) are
shown. For all figure parts: some error bars are too small for
visualization. *p,0.05, ***p,0.001 using t-tests (see methods).
(PDF)
Figure S5 Imatinib inhibits proliferation in the pres-
ence of doxorubicin via STAT3-dependent and indepen-
dent mechanisms. (A–C) 435s/M14 cells stably expressing
pcDNA or STAT3C cells were treated with doxorubicin/imatinib
(72 h), and analyzed by CellTiter-Glo viability assay (A), tritiated
thymidine assay (B), or BrdU/PI FACS analysis (C). Represen-
tative experiments are shown on the left and Mean6SEM for
three independent experiments are shown on the right (A,B,C). In
some cases, error bars are too small to visualize. **p#0.01 using t-
tests (see methods).
(PDF)
Figure S6 Imatinib potentiates doxorubicin-mediated
inhibition of NF-kB targets. (A, B) 435s/M14 cells were
treated with imatinib (40 h) (A) or transfected with c-Abl/Arg
siRNAs (B), and nuclear fractions analyzed by Western blot.
Graphs are Mean6SEM from 3 independent experiments.
WCL=whole cell lysate. (C) 435s/M14 cells stably expressing a
3X-NF-kB-luciferase reporter were treated with vehicle/imatinib
(8 h) in the absence or presence of TNFa, and luciferase activity
assessed. Mean6SEM for 3 independent experiments. (D,E)
Graphical representation of Western blots (left) for data shown in
Fig. 7C,D. Mean6SEM for 3 independent experiments. (F) A
second graphical representation (Mean6SEM for 3 independent
experiments) for PARP cleavage data presented in Fig. 7E, left,
which demonstrates that the rescue of PARP cleavage following
silencing p65 is not complete. For all subfigures: some error bars
are too small to visualize. *p,0.05, **p#0.01, ***p,0.001 (see
methods).
(PDF)
Figure S7 Imatinib inhibits induction of a STAT3-
dependent HSP27/p38/Akt survival pathway in re-
sponse to doxorubicin treatment. (A) Graphical representa-
tion of Western blots described in Fig. 9A. Mean6SEM for 3
independent experiments. (B) 435s/M14-DR cells were treated
with imatinib and/or doxorubicin (40 h), and lysates from
attached and detached cells were analyzed by Western blot.
Graph represents Mean6SEM for 3 independent experiments. (C)
435s/M14 cells, transfected with STAT3 siRNA, were treated
with doxorubicin (40h), and lysates blotted with antibodies.
Graphs represent Mean6SEM from 3 independent experiments
for data described in Fig. 9B. For all subfigures: some error bars
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